Grandfield & Dodd, LLC Vertex Pharmaceuticals Inc Transaction History

Grandfield & Dodd, LLC

$1.5 Billion
Q1 2024

A detailed history of Grandfield & Dodd, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 9,115 shares of VRTX stock, worth $4.48 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

9,115

Previous 8,986 1.44%

Holding current value

$4.48 Million

Previous $3.66 Million 4.21%

% of portfolio

0.25%

Previous 0.27%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$407.69 - $446.08 $52,592 - $57,544	129 Added 1.44%	9,115 $3.81 Million
Q4 2023 Jan 31, 2024	BUY	$343.0 - $410.68 $25,725 - $30,801	75 Added 0.84%	8,986 $3.66 Million
Q3 2023 Oct 25, 2023	SELL	$338.18 - $362.46 $36,185 - $38,783	-107 Reduced 1.19%	8,911 $3.1 Million
Q2 2023 Aug 07, 2023	BUY	$314.42 - $351.91 $9,432 - $10,557	30 Added 0.33%	9,018 $3.17 Million
Q1 2023 Apr 28, 2023	BUY	$283.23 - $323.1 $42,767 - $48,788	151 Added 1.71%	8,988 $2.83 Million

Q4 2022 Jan 20, 2023	BUY	$285.76 - $321.48 $66,867 - $75,226	234 Added 2.72%	8,837 $0
Q2 2022 Aug 01, 2022	BUY	$234.96 - $292.55 $3,054 - $3,803	13 Added 0.15%	8,603 $2.42 Million
Q1 2022 Apr 19, 2022	BUY	$221.42 - $260.97 $33,213 - $39,145	150 Added 1.78%	8,590 $2.24 Million
Q4 2021 Feb 08, 2022	BUY	$177.01 - $223.45 $91,868 - $115,970	519 Added 6.55%	8,440 $1.85 Million
Q3 2021 Oct 28, 2021	SELL	$181.39 - $202.99 $1,995 - $2,232	-11 Reduced 0.14%	7,921 $1.44 Million
Q2 2021 Jul 28, 2021	BUY	$187.49 - $221.1 $13,124 - $15,477	70 Added 0.89%	7,932 $1.6 Million
Q1 2021 Apr 22, 2021	BUY	$207.02 - $241.31 $3,933 - $4,584	19 Added 0.24%	7,862 $1.69 Million
Q4 2020 Jan 29, 2021	BUY	$207.01 - $276.09 $45,749 - $61,015	221 Added 2.9%	7,843 $1.85 Million
Q3 2020 Nov 03, 2020	BUY	$255.65 - $303.1 $9,714 - $11,517	38 Added 0.5%	7,622 $2.07 Million
Q2 2020 Jul 24, 2020	BUY	$225.48 - $295.8 $32,694 - $42,891	145 Added 1.95%	7,584 $2.2 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $29,366 - $36,428	147 Added 2.02%	7,439 $1.77 Million
Q4 2019 Feb 07, 2020	BUY	$166.71 - $223.91 $47,512 - $63,814	285 Added 4.07%	7,292 $1.6 Million
Q3 2019 Oct 30, 2019	BUY	$166.23 - $187.09 $68,985 - $77,642	415 Added 6.3%	7,007 $1.19 Million
Q2 2019 Jul 29, 2019	BUY	$164.61 - $190.37 $51,358 - $59,395	312 Added 4.97%	6,592 $1.21 Million
Q1 2019 Apr 26, 2019	BUY	$163.73 - $194.7 $6,712 - $7,982	41 Added 0.66%	6,280 $1.16 Million
Q4 2018 Feb 12, 2019	BUY	$151.91 - $192.21 $9,266 - $11,724	61 Added 0.99%	6,239 $1.03 Million
Q3 2018 Nov 02, 2018	BUY	$167.73 - $192.74 $7,547 - $8,673	45 Added 0.73%	6,178 $1.19 Million
Q2 2018 Jul 27, 2018	BUY	$145.72 - $169.96 $2,185 - $2,549	15 Added 0.25%	6,133 $1.04 Million
Q1 2018 May 04, 2018	SELL	$151.6 - $177.13 $19,708 - $23,026	-130 Reduced 2.08%	6,118 $997,000
Q4 2017 Feb 06, 2018	BUY	$137.28 - $155.55 $14,139 - $16,021	103 Added 1.68%	6,248 $936,000
Q3 2017 Nov 03, 2017	BUY	$148.13 - $162.24 $910,258 - $996,964	6,145	6,145 $934,000

Others Institutions Holding VRTX

# of Institutions

1,637

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $126B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandfield & Dodd, LLC with notifications on news.

Account

Grandfield & Dodd, LLC Vertex Pharmaceuticals Inc Transaction History